标题
Type I interferon-mediated tumor immunity and its role in immunotherapy
作者
关键词
-
出版物
CELLULAR AND MOLECULAR LIFE SCIENCES
Volume 79, Issue 3, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-03-16
DOI
10.1007/s00018-022-04219-z
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Inhibition of interferon-signalling halts cancer-associated fibroblast-dependent protection of breast cancer cells from chemotherapy
- (2021) Robyn V. Broad et al. BRITISH JOURNAL OF CANCER
- Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective
- (2021) Egle Ramelyte et al. CANCER CELL
- Lactobacillus rhamnosus GG induces cGAS/STING- dependent type I interferon and improves response to immune checkpoint blockade
- (2021) Wei Si et al. GUT
- Combination immunotherapy strategies for glioblastoma
- (2021) Hok Yee Chan et al. JOURNAL OF NEURO-ONCOLOGY
- Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling
- (2021) Michael C. Brown et al. Nature Communications
- Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination
- (2021) D. G. Roy et al. Nature Communications
- ExoSTING, an extracellular vesicle loaded with STING agonists, promotes tumor immune surveillance
- (2021) Su Chul Jang et al. Communications Biology
- Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants
- (2021) Sachin Bhagchandani et al. ADVANCED DRUG DELIVERY REVIEWS
- 1036O Relatlimab (RELA) + nivolumab (NIVO) vs. NIVO in previously untreated metastatic or unresectable melanoma: Additional efficacy in RELATIVITY-047
- (2021) F.S. Hodi et al. ANNALS OF ONCOLOGY
- Simultaneous targeting of TGF-β/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion
- (2021) Yan Lan et al. CANCER CELL
- BDB001, an intravenously administered toll-like receptor 7 and 8 (TLR7/8) agonist, in combination with pembrolizumab in advanced solid tumors: Phase 1 safety and efficacy results.
- (2021) Manish R. Patel et al. JOURNAL OF CLINICAL ONCOLOGY
- Preliminary results from a phase 1/2 study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors.
- (2021) Manish Sharma et al. JOURNAL OF CLINICAL ONCOLOGY
- STING suppresses bone cancer pain via immune and neuronal modulation
- (2021) Kaiyuan Wang et al. Nature Communications
- STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer
- (2021) Seung Joon Lee et al. Journal for ImmunoTherapy of Cancer
- Pulmonary Delivery of Nanoparticle-Bound Toll-Like Receptor 9 Agonist for the Treatment of Metastatic Lung Cancer
- (2020) Jillian L. Perry et al. ACS Nano
- CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study
- (2020) Jyoti Mayadev et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- STING and IRF3 in stromal fibroblasts enable sensing of genomic stress in cancer cells to undermine oncolytic viral therapy
- (2020) Esther N. Arwert et al. NATURE CELL BIOLOGY
- Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity
- (2020) Daniel S. Leventhal et al. Nature Communications
- Telomere Stress Potentiates STING-Dependent Anti-tumor Immunity
- (2020) Ilgen Mender et al. CANCER CELL
- Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study
- (2020) Kevin J Harrington et al. CLINICAL CANCER RESEARCH
- Structures and Mechanisms in the cGAS-STING Innate Immunity Pathway
- (2020) Xuewu Zhang et al. IMMUNITY
- Oncolytic virus-derived type I interferon restricts CAR T cell therapy
- (2020) Laura Evgin et al. Nature Communications
- 1083MO Final results from ILLUMINATE-204, a phase I/II trial of intratumoral tilsotolimod in combination with ipilimumab in PD-1 inhibitor refractory advanced melanoma
- (2020) C. Haymaker et al. ANNALS OF ONCOLOGY
- Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy
- (2020) Mengze Lv et al. CELL RESEARCH
- In situ immunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapy
- (2020) Yinwen Cheng et al. Journal for ImmunoTherapy of Cancer
- STING agonist promotes CAR T cell trafficking and persistence in breast cancer
- (2020) Nuo Xu et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Enhancing anti-tumour efficacy with immunotherapy combinations
- (2020) Funda Meric-Bernstam et al. LANCET
- First-in-Human Phase I Clinical Trial of an SFV-Based RNA Replicon Cancer Vaccine against HPV-Induced Cancers
- (2020) Fenne L. Komdeur et al. MOLECULAR THERAPY
- Interferons α and β in cancer: therapeutic opportunities from new insights
- (2019) Ernest C. Borden NATURE REVIEWS DRUG DISCOVERY
- Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response
- (2019) Camilla Salvagno et al. NATURE CELL BIOLOGY
- Shared and Distinct Functions of Type I and Type III Interferons
- (2019) Helen M. Lazear et al. IMMUNITY
- Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas.
- (2019) Funda Meric-Bernstam et al. JOURNAL OF CLINICAL ONCOLOGY
- ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy.
- (2019) Marcus O. Butler et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunotherapeutic effects of intratumoral nanoplexed poly I:C
- (2019) M. Angela Aznar et al. Journal for ImmunoTherapy of Cancer
- Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma
- (2019) Lisa H. Butterfield et al. Journal for ImmunoTherapy of Cancer
- A molecular switch from STAT2-IRF9 to ISGF3 underlies interferon-induced gene transcription
- (2019) Ekaterini Platanitis et al. Nature Communications
- Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade
- (2019) Nicolas Jacquelot et al. CELL RESEARCH
- Type I IFN protects cancer cells from CD8+ T cell–mediated cytotoxicity after radiation
- (2019) Jianzhou Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- SLC19A1 transports immunoreactive cyclic dinucleotides
- (2019) Rutger D. Luteijn et al. NATURE
- Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors
- (2019) Kerstin Kapp et al. OncoImmunology
- Lyophilizable and Multifaceted Toll-like Receptor 7/8 Agonist-Loaded Nanoemulsion for the Reprogramming of Tumor Microenvironments and Enhanced Cancer Immunotherapy
- (2019) Sun-Young Kim et al. ACS Nano
- 1310OAdjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial
- (2019) J S Weber et al. ANNALS OF ONCOLOGY
- Type I Interferon Delivery by iPSC-Derived Myeloid Cells Elicits Antitumor Immunity via XCR1+ Dendritic Cells
- (2019) Nobuhiro Tsuchiya et al. Cell Reports
- TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma
- (2019) Matthew J. Reilley et al. Journal for ImmunoTherapy of Cancer
- Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study
- (2019) Suresh Senan et al. Clinical Lung Cancer
- Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study
- (2019) Rina Hui et al. LANCET ONCOLOGY
- Manganese Increases the Sensitivity of the cGAS-STING Pathway for Double-Stranded DNA and Is Required for the Host Defense against DNA Viruses
- (2018) Chenguang Wang et al. IMMUNITY
- PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy
- (2018) Dmitriy Zamarin et al. JOURNAL OF CLINICAL INVESTIGATION
- Recurrent Glioblastoma Treated with Recombinant Poliovirus
- (2018) Annick Desjardins et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy
- (2018) Marie-Claude Bourgeois-Daigneault et al. Science Translational Medicine
- Eradication of spontaneous malignancy by local immunotherapy
- (2018) Idit Sagiv-Barfi et al. Science Translational Medicine
- Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette–Guérin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma
- (2018) Jessica Da Gama Duarte et al. Frontiers in Immunology
- Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: Results from the exploratory, controlled, randomized, international phase 2 IMPULSE study
- (2018) M Thomas et al. ANNALS OF ONCOLOGY
- In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma
- (2018) Matthew J. Frank et al. Cancer Discovery
- SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study
- (2018) Antoni Ribas et al. Cancer Discovery
- Nanoparticle-Conjugate TLR7/8 Agonist Localized Immunotherapy Provokes Safe Antitumoral Responses
- (2018) Lutz Nuhn et al. ADVANCED MATERIALS
- Intratumoral IFN-α gene delivery reduces tumor-infiltrating regulatory T cells through the downregulation of tumor CCL17 expression
- (2018) Aya Hirata et al. CANCER GENE THERAPY
- Tumor-Derived cGAMP Triggers a STING-Mediated Interferon Response in Non-tumor Cells to Activate the NK Cell Response
- (2018) Assaf Marcus et al. IMMUNITY
- Toll-like receptor 3 agonist poly I:C reinforces the potency of cytotoxic chemotherapy via the TLR3-UNC93B1-IFN-β signaling axis in paclitaxel-resistant colon cancer
- (2018) Jiaojiao Zhao et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Type I IFN blockade uncouples immunotherapy-induced antitumor immunity and autoimmune toxicity
- (2018) Scott R. Walsh et al. JOURNAL OF CLINICAL INVESTIGATION
- Regulatory T cells in the treatment of disease
- (2018) Amir Sharabi et al. NATURE REVIEWS DRUG DISCOVERY
- Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity
- (2018) Kelsey E. Sivick et al. Cell Reports
- Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model
- (2018) Lukasz Kuryk et al. OncoImmunology
- Trial Watch: Toll-like receptor agonists in cancer immunotherapy
- (2018) Melody Smith et al. OncoImmunology
- Mitotic progression following DNA damage enables pattern recognition within micronuclei
- (2017) Shane M. Harding et al. NATURE
- cGAS is essential for the antitumor effect of immune checkpoint blockade
- (2017) Hua Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers
- (2017) Claire Lhuillier et al. SEMINARS IN CANCER BIOLOGY
- DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
- (2017) Claire Vanpouille-Box et al. Nature Communications
- Neoadjuvant Interferons: Critical for Effective PD-1–Based Immunotherapy in TNBC
- (2017) Natasha K. Brockwell et al. Cancer Immunology Research
- Growing tumors induce a local STING dependent Type I IFN response in dendritic cells
- (2016) Lisa Andzinski et al. INTERNATIONAL JOURNAL OF CANCER
- The host STING pathway at the interface of cancer and immunity
- (2016) Leticia Corrales et al. JOURNAL OF CLINICAL INVESTIGATION
- Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma
- (2016) Igor Puzanov et al. JOURNAL OF CLINICAL ONCOLOGY
- Activated human mesenchymal stem/stromal cells suppress metastatic features of MDA-MB-231 cells by secreting IFN-β
- (2016) N Yoon et al. Cell Death & Disease
- The Essential Role of Type I Interferons in Differentiation and Activation of Tumor-Associated Neutrophils
- (2016) Ekaterina Pylaeva et al. Frontiers in Immunology
- Trial Watch: Immunotherapy plus radiation therapy for oncological indications
- (2016) Erika Vacchelli et al. OncoImmunology
- Current clinical trials testing the combination of immunotherapy with radiotherapy
- (2016) Josephine Kang et al. Journal for ImmunoTherapy of Cancer
- Suppression of Intratumoral CCL22 by Type I Interferon Inhibits Migration of Regulatory T Cells and Blocks Cancer Progression
- (2015) David Anz et al. CANCER RESEARCH
- Positive feedback regulation of type I interferon by the interferon-stimulated gene STING
- (2015) F. Ma et al. EMBO REPORTS
- Phase I clinical study of the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumours
- (2015) Martin R. Weihrauch et al. EUROPEAN JOURNAL OF CANCER
- The lack of type I interferon induces neutrophil-mediated pre-metastatic niche formation in the mouse lung
- (2015) Ching-Fang Wu et al. INTERNATIONAL JOURNAL OF CANCER
- Type IIFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human
- (2015) Lisa Andzinski et al. INTERNATIONAL JOURNAL OF CANCER
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- (2015) Robert H.I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity
- (2015) Olivier Demaria et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity
- (2015) Leticia Corrales et al. Cell Reports
- Targeting the Tumor Microenvironment with Interferon-β Bridges Innate and Adaptive Immune Responses
- (2014) Xuanming Yang et al. CANCER CELL
- Type I IFN gene delivery suppresses regulatory T cells within tumors
- (2014) H Hashimoto et al. CANCER GENE THERAPY
- Fatty Acid-Binding Protein E-FABP Restricts Tumor Growth by Promoting IFN- Responses in Tumor-Associated Macrophages
- (2014) Y. Zhang et al. CANCER RESEARCH
- Strict Requirement for Vector-Induced Type I Interferon in Efficacious Antitumor Responses to Virally Encoded IL12
- (2014) I. Melero et al. CANCER RESEARCH
- Expansion of circulating CD56brightnatural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α
- (2014) Caroline H. Riley et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
- (2014) Seng-Ryong Woo et al. IMMUNITY
- STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors
- (2014) Liufu Deng et al. IMMUNITY
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- (2014) Eugene D Kwon et al. LANCET ONCOLOGY
- Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
- (2014) Antonella Sistigu et al. NATURE MEDICINE
- Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
- (2014) D. Zamarin et al. Science Translational Medicine
- Immune Cell-Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation
- (2014) T. Bald et al. Cancer Discovery
- Trial Watch
- (2014) Fernando Aranda et al. OncoImmunology
- Interferon- Suppresses cAMP to Disarm Human Regulatory T Cells
- (2013) N. Bacher et al. CANCER RESEARCH
- Cyclic [G(2′,5′)pA(3′,5′)p] Is the Metazoan Second Messenger Produced by DNA-Activated Cyclic GMP-AMP Synthase
- (2013) Pu Gao et al. CELL
- hIFN-α gene modification augments human natural killer cell line anti-human hepatocellular carcinoma function
- (2013) W Jiang et al. GENE THERAPY
- CXCR2-mediated tumor-associated neutrophil recruitment is regulated by IFN-β
- (2013) J. Jablonska et al. INTERNATIONAL JOURNAL OF CANCER
- Cutting Edge: DNA Sensing via the STING Adaptor in Myeloid Dendritic Cells Induces Potent Tolerogenic Responses
- (2013) L. Huang et al. JOURNAL OF IMMUNOLOGY
- Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP
- (2013) Andrea Ablasser et al. NATURE
- Impaired IFN- Production by Plasmacytoid Dendritic Cells Favors Regulatory T-cell Expansion That May Contribute to Breast Cancer Progression
- (2012) V. Sisirak et al. CANCER RESEARCH
- The JAK-STAT Pathway at Twenty
- (2012) George R. Stark et al. IMMUNITY
- Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells
- (2012) Barbara Drobits et al. JOURNAL OF CLINICAL INVESTIGATION
- Cyclic GMP-AMP Is an Endogenous Second Messenger in Innate Immune Signaling by Cytosolic DNA
- (2012) J. Wu et al. SCIENCE
- IFN Produced by TLR4-Activated Tumor Cells Is Involved in Improving the Antitumoral Immune Response
- (2011) N. G. Nunez et al. CANCER RESEARCH
- The Efficacy of Radiotherapy Relies upon Induction of Type I Interferon-Dependent Innate and Adaptive Immunity
- (2011) B. C. Burnette et al. CANCER RESEARCH
- Direct Effects of Type I Interferons on Cells of the Immune System
- (2011) S. Hervas-Stubbs et al. CLINICAL CANCER RESEARCH
- CpG Blocks Immunosuppression by Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
- (2011) C. Zoglmeier et al. CLINICAL CANCER RESEARCH
- Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer
- (2011) Primo N. Lara et al. JOURNAL OF CLINICAL ONCOLOGY
- Host type I IFN signals are required for antitumor CD8+T cell responses through CD8α+dendritic cells
- (2011) Mercedes B. Fuertes et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
- (2011) J. Stagg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Neutrophils responsive to endogenous IFN-β regulate tumor angiogenesis and growth in a mouse tumor model
- (2010) Jadwiga Jablonska et al. JOURNAL OF CLINICAL INVESTIGATION
- In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
- (2010) Joshua D. Brody et al. JOURNAL OF CLINICAL ONCOLOGY
- Bacteria-Induced Gap Junctions in Tumors Favor Antigen Cross-Presentation and Antitumor Immunity
- (2010) F. Saccheri et al. Science Translational Medicine
- Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists
- (2009) Jörg Vollmer et al. ADVANCED DRUG DELIVERY REVIEWS
- Horizontal transfer of tumor DNA to endothelial cells in vivo
- (2009) J Ehnfors et al. CELL DEATH AND DIFFERENTIATION
- Identification of a dendritic cell receptor that couples sensing of necrosis to immunity
- (2009) David Sancho et al. NATURE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started